fosfomycin and Chronic-Disease

Topics: Anti-Infective Agents, Urinary; Bacteriuria; Cephalosporins; Chronic Disease; Cystitis; Drug Resistance, Bacterial; Fluoroquinolones; Fosfomycin; Humans; Microbial Sensitivity Tests; Nitrofurantoin; Pyelonephritis; Recurrence; Risk Factors; Sepsis; Tromethamine; Urinary Tract Infections

effects of Fosfomycin (FOM) nebulizer therapy were studied in patients with chronic sinusitis.. about 28 patients with chronic sinusitis were administered 2 ml of FOM sodium (3% w/v) by nebulizer three times per week for 4 weeks. Levels of IL-1 beta, IL-6, IL-8, and TNF-alpha in nasal lavage were also measured before and at the end of treatment.. the overall efficacy of this treatment on the basis of both subjective and objective symptoms, was 'excellent' for 28.6%, 'good' for 10.7%, 'fair' for 39.4%, and yield 'no change' for 21.4% of the patients. Both IL-1 beta and IL-6 concentrations were significantly decreased after treatment. Although the IL-8 level did not significantly decrease, it seems to be related to the overall efficacy. TNF-alpha was not detected in all of the samples.. FOM nebulization therapy is highly effective in treatment for chronic sinusitis, and efficacy may be due to an immunomodulatory mechanism, as well as its bactericidal effect.

Topics: Adolescent; Adult; Aged; Child; Chronic Disease; Drug Administration Schedule; Exudates and Transudates; Female; Fosfomycin; Haemophilus Infections; Humans; Interleukins; Male; Middle Aged; Nebulizers and Vaporizers; Sinusitis; Streptococcal Infections; Treatment Outcome; Tumor Necrosis Factor-alpha

Carumonam (CRMN), the first monobactam antibiotic in Japan, has excellent activity against gram-negative bacteria and is useful in the treatment of urinary tract infections. However, it may be insufficient in the treatment of complicated urinary tract infections because of the increase in isolation of gram-positive bacteria, and it may be necessary to co-administer antibiotics active against gram-positive organisms to achieve a broader spectrum of coverage in connection with severe infections. The combination of CRMN and fosfomycin (FOM) was evaluated for its effectiveness and safety at the Department of Urology, Yamagata University Hospital and 7 affiliated hospitals. Clinical efficacy was assessed on 64 patients with complicated urinary tract infection according to the Criteria for Clinical Evaluation of Antimicrobial Agents in UTI (3rd. ed.) recommended by the Japan UTI Committee. Clinical efficacy was evaluated as excellent in 16, moderate in 32, poor in 16, with an overall clinical effectiveness rate of 75.0%, which is superior compared with CRMN alone. Of the total of 92 bacterial strains isolated, 66 (71.7%) were eradicated. Subjective adverse reaction was seen in 1 patient (1.4%), as nausea and anorexia. Slight increases in serum GOT and GPT ware recorded in 5 patients (7.1%). These findings disappeared after the termination of administration without treatment. The combination of CRMN and FOM might therefore be useful in the treatment of complicated urinary tract infections.

Topics: Adult; Aged; Aged, 80 and over; Aztreonam; Chronic Disease; Drug Therapy, Combination; Female; Fosfomycin; Humans; Male; Middle Aged; Urinary Tract Infections

Chronic bacterial prostatitis (CBP) is a difficult-to-treat infection as only a few antibiotics achieve therapeutic concentrations in the prostate. Data on the efficacy and safety of oral fosfomycin for the treatment of CBP are limited.. To analyse the efficacy and safety of fosfomycin in CBP due to MDR pathogens.. In a prospective observational study, an oral regimen of 3 g of fosfomycin q24h for 1 week followed by 3 g q48h for a treatment duration of 6-12 weeks was administered. The outcome was clinical and microbiological cure rate at the end of treatment (EOT) and rate of relapse at 3 and 6 months.. The study included 44 patients. The most common pathogen was Escherichia coli (66%), followed by Klebsiella spp. (14%) and Enterococcus faecalis (14%). Most strains were MDR (59%) and 23% had an ESBL phenotype; 33 of 44 strains were resistant to fluoroquinolones, but all were susceptible to fosfomycin (median MIC for Gram-negative pathogens 1.5 mg/L). In 25 patients, treatment was administered for 6 weeks, whereas in the remaining 19 patients it was prolonged to 12 weeks based on the presence of calcifications in the prostate. Cure rate was 82% at EOT and 80% and 73% at 3 and 6 months accordingly. Microbiological eradication was achieved in 86% and 77% at EOT and at 6 months, respectively. Failure was observed in 12 patients. The most common adverse event was diarrhoea (18%).. Oral fosfomycin, particularly in the era of MDR prevalence, represents an attractive, safe and effective alternative to fluoroquinolones for the treatment of CBP.

Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Chronic Disease; Drug Resistance, Multiple, Bacterial; Enterococcus faecalis; Escherichia coli; Fosfomycin; Humans; Klebsiella; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Prostatitis

Recurrent lower urinary tract infections (UTI) in women are one of the most challenging problems of modern urology, which is associated both with their high incidence and increasing resistance of uropathogens to antibacterial drugs. Due to this fact, the phytotherapy of infectious and inflammatory diseases of the urinary tract has received increased attention.. To investigate the effectiveness of Phytolysin nefroCAPS in the complex management of women with chronic recurrent cystitis.. 50 women with chronic recurrent cystitis underwent a complex examination. They were divided into two groups depending on the treatment they received. Patients of the 1st group (n=27) received a combination therapy: fosfomycin (monural) 3 g (single dose) and Phytolysin nefroCAPS one capsule three times daily for three months. Patients of the 2nd group (n=23) were administered a single 3-g dose of fosfomycin (monural).. Follow-up examinations were performed 1, 3 and six months after initiation of the treatment. In patients of the 1st group, clinical manifestations of the disease disappeared earlier, and they had fewer recurrences than the patients of the 2nd group. Also, bacteriological study of urine showed a more persistent antimicrobial effect among patients of the 1st group.. In patients with chronic recurrent cystitis, plant-based preparation Phytolysin nefroCAPS administered concurrently with an antibacterial drug is more effective than antibiotic monotherapy.

Topics: Adult; Aged; Anti-Bacterial Agents; Capsules; Chronic Disease; Cystitis; Diuresis; Drug Therapy, Combination; Female; Fosfomycin; Humans; Middle Aged; Pelvic Pain; Plant Preparations; Recurrence; Treatment Outcome; Young Adult

Evaluation of the efficacy and safety of Phytolysin in complex treatment of female patients with chronic cystitis.. 40 women with chronic cystitis were examined from January 2016 to March 2016. Depending on the treatment, all patients were divided into two groups of 20 people. Main group of patients was treated with Fosfomycin (Monural) and Phytolysin. Control group of patients received monotherapy with fosfomycin.. The results were assessed at 1 and 2 months after initiation of therapy. Rapid normalization of the status and laboratory parameters, improvement of dynamics of the endoscopic view was observed in main group of patients.. The complex of biologically active substances contained in Phytolysin has antimicrobial, anti-inflammatory, antispasmodic, and immunomodulatory effects, promotes the normalization of urodynamics of lower urinary tract, reduces the risk of relapse of chronic recurrent cystitis. Thus, Phytolysin can be recommended as a component of complex therapy of exacerbations of chronic cystitis, as well as a drug for prevention of the disease in disease-free periods.

Topics: Adult; Aged; Anti-Bacterial Agents; Case-Control Studies; Chronic Disease; Cystitis; Drug Therapy, Combination; Female; Fosfomycin; Humans; Middle Aged; Plant Extracts; Young Adult

Studies on a combination therapy of fosfomycin (FOM) and norfloxacin (NFLX) against chronic otitis media were performed, and the following results were obtained. 1. The fractional inhibitory concentration index (FIC index) < or = 0.5 between FOM and NFLX showed 66.7% (4/6) against S. aureus isolated from chronic otitis media and 80.5% (4/5) against P. aeruginosa. 2. Clinical effects was excellent in 2 cases (18.2%), good in 6 cases (54.5%) and poor in 3 cases (27.3%). 3. Bacteriologically 9 strains out of 11 patients were eradicated after the combination treatment; 5/6 in S. aureus and 4/5 in P. aeruginosa. 4. No adverse effect and abnormal laboratory findings were observed in this study. It is suggested that the combination of FOM otic solution and NFLX is useful for the treatment of chronic otitis media.

Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; Drug Therapy, Combination; Fosfomycin; Humans; Norfloxacin; Otitis Media; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus

We present a case of toxic shock syndrome (TSS) induced by MRSA after sinus surgery. The patient was a 64-year-old woman who had undergone sinus surgery because of chronic sinusitis. Nine days after the surgery, she began to have sore throat, fever, and diffuse erythroderma followed by severe hypotension and renal dysfunction. Culture of sputum, nasal discharge and stool showed MRSA. Blood culture was negative. She was treated with intravenous fluids, catecholamines and antibiotics (vancomycin and fosfomycin). Continuous hemodiafiltration was started because of oliguria. Her condition improved gradually and she was discharged about a month after the onset of her illness. We should recognize that TSS can occur as a fatal complication after nasal surgery.

Topics: Chronic Disease; Drug Therapy, Combination; Female; Fosfomycin; Hemodiafiltration; Humans; Methicillin Resistance; Middle Aged; Postoperative Complications; Shock, Septic; Sinusitis; Staphylococcal Infections; Vancomycin

Authors have carried out a retrospective study in vitro on the bacteria isolated from renal parenchyma and stones in patients with CPN associated to kidney stones. Results show a different inhibitory action of the some antibiotics to Proteus, E. coli and P. aeruginosa. Fosfomycin inhibits the growth of bacteria in a wide range of concentration (50-1000 microgram/ml). A prospective study in vivo shows an excellent therapeutic action of fosfomycin in recurrent urinary infections, and a very good one in CPN and in some forms associated to kidney stones.

Topics: Adult; Aged; Anti-Bacterial Agents; Chronic Disease; Dose-Response Relationship, Drug; Escherichia coli; Female; Fosfomycin; Humans; Kidney Calculi; Male; Middle Aged; Proteus; Pseudomonas aeruginosa; Pyelonephritis

Topics: Anti-Bacterial Agents; Bronchial Diseases; Bronchopneumonia; Chronic Disease; Fosfomycin; Humans

This report deals with the study made of the treatment of 45 acute, subacute and chronic urinary infections in a department of general medicine. 43 of these were infections caused by a single species of bacteria and 3 were caused by more than one species. The sensitivity test of the isolated organisms (E. coli, Proteus, Serratia, Pseudomonas, Klebsiella and S. faecalis) showed 83.33% of the strains to be senstive and 16.8% of the strains to be resistant. Nevertheless, this last group of strains, with the exception of one Pseudomonas, proved to be sensitive to the association of fosfomycin with a beta-lactamin (carbenicillin, amoxycillin) or an aminoglycoside (gentamicin, tobramycin). Of a total of 45 cases, 34 were exclusively treated with fosfomycin (2 g by the intramuscular route and 2 g by the oral route) and 11 cases were treated with a double association of fosfomycin with a beta-lactamin (carbenicillin or amoxycillin) or an aminoglycoside (gentamicin), after having studied the bactericidal activity of the association in vitro. The clinical and bacteriological results were verified 4 weeks after the conclusion of the treatment and showed that there was an eradication of the urinary infection in 34 cases (75.55%), relapses in 6 cases (13.33%) and reinfections in 5 cases (11.22%). These results would seem to be favourable with regards to hospital infections and with respect to organisms that are considered to be very little sensitive or resistant.

Topics: Acute Disease; Anti-Bacterial Agents; Chronic Disease; Follow-Up Studies; Fosfomycin; Humans; Recurrence; Urinary Tract Infections

Fosfomycin has been tested in 25 adult patients with bronchial or bronchopulmonary acute processes, of which 13 were simple acute processes of a greater or lesser severity, and 12 acutenesses of chronic bronchial processes. The germs found most frequently in the sputum cultures were Streptococcus pneumoniae and Klebsiella. Fosfomycin was used intramuscularly with doses of 4 g/day, for an average of 10 days. The results obtained were 16 cures, 7 improvements and 2 failures, which represents 92% success with 8% failures.

Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Drug Evaluation; Female; Fosfomycin; Humans; Injections, Intramuscular; Male; Middle Aged; Sputum

A group of 24 patients with suppurated chronic processes of the medial ear have been treated with fosfomycin. All the cases were studied bacteriologically, isolating in the pus or exudates pathogenic bacterial flora, in which P. aeruginosa (40%) of the isolations) and S. aureus (23%) predominated. The sensitiveness of the strains isolated to fosfomycin was 94%. The results obtained were 21 clinical cures accompanied by the sterility of the exudates and 3 failures, which represents 87.5% success and 12.5% failures. These results are considered very satisfactory in view of the complexity and chronicity of the processes treated. It is also pointed out that fosfomycin totally lacks ototoxicity, being, therefore, a suitable antibiotic for treating chronic infectious processes of the ear.

Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Chronic Disease; Drug Evaluation; Female; Fosfomycin; Humans; Male; Middle Aged; Otitis Media; Time Factors

Fosfomycin has been used on 40 patients with serious urinary infections of different clinical nature, and produced by repetitive infection (prostatisms, carcinomas, lithiasis, hydronephrosis, etc.) The following were isolated in the urocultures: E. coli (60%), Klebsiella (15%), P. aeruginosa (15.0%), Proteus sp. (15.0%), Staphylococcus (5%), S. faecalis (2.5%) and Paracolobactrum coliforme (2.5%). All the germs isolated before treatment were sensitive to fosfomycin. The results, as regards response to the bacteriuria, were 71.4% eradication of the infection, 17.2% reinfections and 11.4% failures. The results are considered very satisfactory in view of the etiopathogenic nature of the processes under treatment.

Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Child, Preschool; Chronic Disease; Drug Evaluation; Enterobacteriaceae Infections; Female; Fosfomycin; Humans; Male; Middle Aged; Pseudomonas Infections; Staphylococcal Infections; Urinary Tract Infections

A study was made of fosfomycin in the treatment of chronic urinary infection in 51 patients. 72% of the 67 bacteria isolated and tested in the laboratory with discs containing 50 mug of fosfomycin were found to be sensitive to the antibiotic. The majority of E. coli, Klebsiella, P. mirabilis and Ps. aeruginosa strains were sensitive to the antibiotic. Generally, 60 mg of fosfomycin/kgbody weight was administered intramuscularly 6-hourly for 7-15 days. A clinical and bacteriological cure was obtained in 39 patients (76%), and after 4-6 weeks in 31 patients (61%). Blood and urine fosfomycin levels were determined in seven patients, three with normal renal function, three with moderate renal insufficiency, and one with severe renal insufficiency. The antibiotic levels and elimination time maintained a clear relation with the degree of renal insufficiency.

Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Chronic Disease; Female; Fosfomycin; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Urinary Tract Infections